2023年心力衰竭治疗:脂质降低疗法有没有地方?
1Department of Cardiovascular Diseases, St Anne's University Hospital and Masaryk, University Brno, Brno, Czech Republic.
Current atherosclerosis reports
|December 4, 2023
概括
在心力衰竭中降脂疗法仍然是不确定的. 虽然他类药物对死亡率没有好处,但一些研究表明它具有积极的影响,并且正在研究新的PCSK9抑制剂,用于心力衰竭患者.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭的管理遵循当前的诊断和治疗指南.
- 降脂疗法在心力衰竭中的作用缺乏明确答案.
- 现有证据主要依赖于有限的随机对照试验.
研究的目的:
- 审查心力衰竭中降脂疗法的证据.
- 评估当前对心力衰竭中低脂血症治疗的理解.
- 探索新型降脂剂的潜在作用.
主要方法:
- 现有文献的审查,包括随机对照试验,元分析和队列研究.
- 对最近关于炎症和脂质修饰的发现进行分析.
- 检查PCSK9抑制剂的新兴作用.
主要成果:
- 两项主要试验发现,在心力衰竭中,他类药物对死亡率没有显著的益处.
- 一些元分析和队列研究表明,降脂疗法的潜在益处.
- PCSK9抑制剂对心力衰竭结果的影响是一个活跃的研究领域.
结论:
- 降脂药物通常不建议用于单独治疗心力衰竭.
- 对于心力衰竭患者的降脂疗法,应根据其他已确定的标准进行说明.
- 需要进一步的研究来澄清新型降脂剂在心力衰竭中的作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
671
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
671
Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics
396
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594


